Abstract
Leukemias continue to cause significant mortality in adults and children, and the use of standard cytotoxic chemotherapy has reached a therapeutic plateau. Thus, there is great interest in treatments directed against inappropriately activated cell signaling pathways which stimulate the uncontrolled growth of neoplastic cells. Increasing evidence suggests that the STAT signaling cascade may be one target of these therapies. Signal transducer and activator of transcription (STAT) proteins are critical in mediating the response of hematopoietic cells to a diverse spectrum of cytokines. Constitutive STAT activation is present in many malignancies and has been especially well characterized in acute and chronic leukemias. While STAT activation is a common characteristic of leukemias, the specific pattern of activated STATs and the manner by which STAT activation occurs vary with each disease. STAT tyrosine phosphorylation can occur through inappropriate Jak activation or by direct activation of an oncoprotein such as Bcr/Abl, and STAT serine phosphorylation may play an important role in leukemias as well. Thus, the STAT signaling pathway is an attractive target for therapeutic intervention, and strategies designed to inhibit STAT activation and STAT mediated gene transcription may play an important role in the next generation of anti-leukemia therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D and Hilton DJ . 1999 Cell 98: 597–608
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC and Norton L . 1996 J Clin Oncol 14: 737–744
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JEJ . 1999 Cell 98: 295–303
Carlesso N, Frank DA and Griffin JD . 1996 J Exp Med 183: 811–820
Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG and Druker BJ . 1997 Blood 90: 4947–4952
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R . 1999 Immunity 10: 105–115
Chai SK, Nichols GL and Rothman P . 1997 J Immunol 159: 4720–4728
Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell Jr JE and Kuriyan J . 1998 Cell 93: 827–839
Darnell Jr JE . 1997 Science 277: 1630–1635
de Groot RP, Raaijmakers JA, Lammers JW, Jove R and Koenderman L . 1999 Blood 94: 1108–1112
Frank DA . 1999 Mol Med 5: 432–456
Frank DA, Mahajan S and Ritz J . 1997 J Clin Invest 100: 3140–3148
Frank DA, Majahan S and Ritz J . 1999 Nature Med 5: 444–447
Frank DA and Varticovski L . 1996 Leukemia 10: 1724–1730
Golub TR, Barker GF, Lovett M and Gilliland DG . 1994 Cell 77: 307–316
Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse J-F, Capiod J-C, Delobel J, Weber-Nordt R, Dusanter-Fourt I, Dreyfus F, Groner B and Prin L . 1996 Blood 87: 1692–1697
Harrison DA, Binari R, Nahrenini TS, Gilman M and Perrimon N . 1995 EMBO J 14: 2857–2865
Heaney ML and Golde DW . 1999 N Engl J Med 340: 1649–1660
Holland JF, Frei E, Bast RC, Kufe DW, Morton DL and Weichselbaum RR eds . 1997 Cancer Medicine, 4th edn Williams and Wilkins Baltimore
Ihle JN . 1996 Cell 84: 331–334
Iland H, Laszlo J and Murphy S . 1995 Polycythemia Vera and the Myeloproliferative Disorders Wasserman LR, Berk PD and Berlin NI eds. Saunders Philadelphia pp 292–310
Ilaria Jr RL and Van Etten RA . 1996 J Biol Chem 271: 31704–31710
Kawano F, Yamaguchi K, Nishimura H, Tsuda H and Takatsuki K . 1985 Cancer 55: 851–856
Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C and Morel-Fournier B . 1991 Blood 78: 1198–1204
Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC and Antin JH . 1997 Ann Intern Med 127: 1080–1088
Leonard WJ and O'Shea JJ . 1998 Annu Rev Immunol 16: 293–322
Luo H, Hanratty WP and Dearolf CR . 1995 EMBO J 14: 1412–1420
Marine JC, Topham DJ, McKay C, Wang D, Parganas E, Stravopodis D, Yoshimura A and Ihle JN . 1999 Cell 98: 609–616
Marra F, Choudhury GG and Abboud HE . 1996 J Clin Inv 98: 1218–1230
Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A and Roifman CM . 1996 Nature 379: 645–648
Migone T-S, Lin J-X, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G and Leonard WJ . 1995 Science 269: 79–81
Najean Y, Dresch C and Rain JD . 1994 Br J Haematol 86: 233–235
Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B and Skorski T . 1999 J Exp Med 189: 1229–1242
Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R and Yu H . 1999 Cancer Res 59: 5059–5063
Palmer AM, Mahajan S, Frank D, Gilliland DG and Carroll M . 1997 Blood 90: 178a
Rabinowe SN, Soiffer RJ, Gribben JG, Daley H, Freedman AS, Daley J, Pesek K, Neuberg D, Pinkus G, Leavitt PR, Spector NA, Grossbard ML, Anderson K, Robertson MJ, Mauch P, Chayt-Marcus K, Ritz J and Nadler LM . 1993 Blood 82: 1366–1376
Rozman C and Montserrat E . 1995 New Engl J Med 333: 1052–1057
Sawyers CL . 1999 N Engl J Med 340: 1330–1340
Shuai K, Halpern J, ten Hoeve J, Rao X and Sawyers CL . 1996 Oncogene 13: 247–254
Shuai K, Horvath CM, Huang LHT, Qureshi SA, Cowburn D and Darnell Jr JE . 1994 Cell 76: 821–828
Shuai K, Stark GR, Kerr IM and Darnell Jr JE . 1993 Science 261: 1744–1746
Sillaber C, Gesbert F, Frank DA, Sattler M and Griffin JP . 2000 Blood 95: 2118–2125
Takemoto S, Mulloy JC, Cereseto A, Migone T-S, Patel BKR, Matsuoka M, Yamaguchi K, Takatsuki K, Kamihira S, White JD, Leonard WJ, Waldmann T and Franchini G . 1997 Proc Natl Acad Sci USA 94: 13897–13902
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM and Wiernik PH . 1997 N Engl J Med 337: 1021–1028
Thiesing JT, Ohno-Jones S, Kolibaba KS and Druker BJ . 1999 Blood 94: 100–101a
Verwilghen RL and Boogaerts MA . 1987 Blood Rev 1: 34–46
Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R and Finke J . 1996 Blood 88: 809–816
Wen Z, Zhong Z and Darnell Jr JE . 1995 Cell 82: 241–250
Xia Z, Baer MR, Block AW, Baumann H and Wetzler M . 1998 Cancer Res 58: 3173–3180
Xu X, Kang SH, Heidenreich O, Okerholm M, O'Shea JJ and Nerenberg MI . 1995 J Clin Inv 96: 1548–1555
Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, Shaw LM and Wasik MA . 1996 Proc Natl Acad Sci USA 93: 9148–9153
Zhang X, Blenis J, Li H-C, Schindler C and Chen-Kiang S . 1995 Science 267: 1990–1994
Acknowledgements
This work was supported by NIH grant CA79547 and the Brent Leahey Fund.
Author information
Authors and Affiliations
Rights and permissions
About this article
This article is cited by
-
GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma
Molecular Cancer (2021)
-
TGF-β2 antagonizes IL-6-promoted cell survival
Molecular and Cellular Biochemistry (2019)
-
The effect of Ganoderma lucidum extract on immunological function and identify its anti-tumor immunostimulatory activity based on the biological network
Scientific Reports (2018)
-
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
Leukemia (2018)
-
Single-cell epigenomic variability reveals functional cancer heterogeneity
Genome Biology (2017)